Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
28 Feb 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
4 Apr 24
8-K
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
19 Mar 24
8-K
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
12 Mar 24
8-K
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
1 Mar 24
8-K
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
28 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
18 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 23
8-K
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7 Nov 23
8-K
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
13 Sep 23
Registration and prospectus
S-3ASR
Automatic shelf registration
19 Mar 24
D
$350.00 mm in equity, sold $350.00 mm, 36 investors
11 Mar 24
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Mar 24
S-8
Registration of securities for employees
28 Feb 24
S-8
Registration of securities for employees
7 Nov 23
424B5
Prospectus supplement for primary offering
13 Sep 23
424B5
Prospectus supplement for primary offering
11 Sep 23
S-8
Registration of securities for employees
28 Feb 23
S-8
Registration of securities for employees
14 Nov 22
424B5
Prospectus supplement for primary offering
12 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 22
DEF 14A
Definitive proxy
28 Apr 22
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
29 Apr 19
DEF 14A
Definitive proxy
29 Apr 19
Other
UPLOAD
Letter from SEC
4 Apr 23
CORRESP
Correspondence with SEC
15 Mar 23
UPLOAD
Letter from SEC
14 Feb 23
CORRESP
Correspondence with SEC
19 Jan 23
UPLOAD
Letter from SEC
20 Dec 22
EFFECT
Notice of effectiveness
4 Sep 19
CORRESP
Correspondence with SEC
27 Aug 19
CORRESP
Correspondence with SEC
19 Aug 19
UPLOAD
Letter from SEC
16 Aug 19
EFFECT
Notice of effectiveness
18 Jul 18
Ownership
4
Richard Scott Struthers
22 Apr 24
4
Dana Pizzuti
17 Apr 24
4
Richard Scott Struthers
17 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Richard Scott Struthers
8 Apr 24
144
Notice of proposed sale of securities
4 Apr 24
4
Stephanie Okey
2 Apr 24
144
Notice of proposed sale of securities
28 Mar 24
4
Jeff E. Knight
26 Mar 24
4
Dana Pizzuti
22 Mar 24